Allergy, Asthma & Respiratory Disease

The Korean Academy of Asthma, Allergy and Clinical Immunology (대한천식알레르기학회)
권호 표지
DOI QR코드

DOI QR Code

Precision medicine for the best treatment of chronic obstructive airway disease

만성폐쇄성기도질환의 최적 치료를 위한 정밀의학적 접근

  • Cho, You Sook (Department of Internal Medicine, Asan Medical Center)
  • 조유숙 (울산대학교 서울아산병원 알레르기내과)
  • Received : 2017.10.11
  • Accepted : 2017.12.15
  • Published : 2018.05.31
⟨ Previous Next ⟩

Abstract

Bronchial asthma and chronic obstructive pulmonary disease (COPD) are 2 representative diseases of chronic obstructive inflammatory airway diseases, and both show a wide range of heterogeneity in their clinical features. Although one end of typical asthma and the other end of COPD are clearly different, both diseases share lots of similarities in biological aspects and clinical manifestations. Currently, 2 different guidelines exist for asthma and COPD management, respectively, and in many clinical situations it is not easy to manage patients especially who have both features and show refractoriness to available medications. Since the features of the diseases are remarkably diverse in terms of clinical courses, prognosis and responses to therapeutic drugs, there have been vigorous efforts to classify appropriate subtypes in order to improve management of the diseases. However, dichotomous thinking about asthma and COPD precludes precise classification of the diseases in the real world. In this article, thus, chronic obstructive airway disease (COAD) ranging from asthma particularly in adults to COPD is proposed as 1 target subject to analyze precise classification based on exact phenotyping and endotyping of the diseases. In the current article, the reasonable precision medicine approach is also suggested based on treatable traits of COAD to achieve the best treatment for COAD patients.

Keywords

References

  1. The Global Initiative for Asthma. 2017 GINA report, global strategy for asthma management and prevention [Internet]. Global Initiative for Asthma; c2017 [cited 2017 Oct 7]. Available from: http://ginasthma.org/gina-reports/.
  2. Reid L. The role of chronic bronchitis in the production of "chronic obstructive pulmonary emphysema". J Am Med Womens Assoc 1965;20: 633-8.
  3. Orie NG, Sluiter HJ, De Vries K, Tammeling GJ, Witkop J. The host factor in bronchitis. In: Orie NG, Sluiter HJ, editors. Bronchitis. Assen (The Netherlands): Royal Van Gorcum, 1961.
  4. Cosio BG, Perez de Llano L, Lopez Vina A, Torrego A, Lopez-Campos JL, Soriano JB, et al. Th-2 signature in chronic airway diseases: towards the extinction of asthma-COPD overlap syndrome? Eur Respir J 2017;49. pii: 1602397.
  5. Kim TB, Oh YM, Chang YS, Cho YS, Jang AS, Cho SH, et al. The reality of an intermediate type between asthma and COPD in practice. Respir Care 2012;57:1248-53. https://doi.org/10.4187/respcare.01232
  6. Wheaton AG, Pleasants RA, Croft JB, Ohar JA, Heidari K, Mannino DM, et al. Gender and asthma-chronic obstructive pulmonary disease overlap syndrome. J Asthma 2016;53:720-31. https://doi.org/10.3109/02770903.2016.1154072
  7. Gibson PG. Inflammatory phenotypes in adult asthma: clinical applications. Clin Respir J 2009;3:198-206. https://doi.org/10.1111/j.1752-699X.2009.00162.x
  8. Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006;11:54-61. https://doi.org/10.1111/j.1440-1843.2006.00784.x
  9. Moore WC, Hastie AT, Li X, Li H, Busse WW, Jarjour NN, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol 2014;133:1557-63.e5. https://doi.org/10.1016/j.jaci.2013.10.011
  10. Global Initiative for Chronic Obstructive Lung Disease. GOLD 2017 global strategy for the diagnosis, management and prevention of COPD [Internet]. Global Initiative for Chronic Obstructive Lung Disease; c2018 [cited 2017 Oct 8]. Available from: www.goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/.
  11. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med 2005;172:149-60. https://doi.org/10.1164/rccm.200409-1181PP
  12. Balzar S, Wenzel SE, Chu HW. Transbronchial biopsy as a tool to evaluate small airways in asthma. Eur Respir J 2002;20:254-9. https://doi.org/10.1183/09031936.02.00261102
  13. Elias JA. Airway remodeling in asthma. Unanswered questions. Am J Respir Crit Care Med 2000;161(3 Pt 2):S168-71. https://doi.org/10.1164/ajrccm.161.supplement_2.a1q4-4
  14. Boulet L, Belanger M, Carrier G. Airway responsiveness and bronchial-wall thickness in asthma with or without fixed airflow obstruction. Am J Respir Crit Care Med 1995;152:865-71. https://doi.org/10.1164/ajrccm.152.3.7663797
  15. Benayoun L, Druilhe A, Dombret MC, Aubier M, Pretolani M. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003;167:1360-8. https://doi.org/10.1164/rccm.200209-1030OC
  16. Busse WW, Banks-Schlegel S, Wenzel SE. Pathophysiology of severe asthma. J Allergy Clin Immunol 2000;106:1033-42. https://doi.org/10.1067/mai.2000.111307
  17. Kim TB, Jang AS, Kwon HS, Park JS, Chang YS, Cho SH, et al. Identification of asthma clusters in two independent Korean adult asthma cohorts. Eur Respir J 2013;41:1308-14. https://doi.org/10.1183/09031936.00100811
  18. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010;181:315-23. https://doi.org/10.1164/rccm.200906-0896OC
  19. Hinks TS, Brown T, Lau LC, Rupani H, Barber C, Elliott S, et al. Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1. J Allergy Clin Immunol 2016;138:61-75. https://doi.org/10.1016/j.jaci.2015.11.020
  20. Kuo CS, Pavlidis S, Loza M, Baribaud F, Rowe A, Pandis I, et al. T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. Eur Respir J 2017;49. pii: 1602135.
  21. Marichal T, Mesnil C, Bureau F. Homeostatic eosinophils: characteristics and functions. Front Med (Lausanne) 2017;4:101. https://doi.org/10.3389/fmed.2017.00101
  22. Rothenberg ME. A hidden residential cell in the lung. J Clin Invest 2016; 126:3185-7. https://doi.org/10.1172/JCI89768
  23. Woodruff PG, Agusti A, Roche N, Singh D, Martinez FJ. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet 2015; 385:1789-98. https://doi.org/10.1016/S0140-6736(15)60693-6
  24. Bafadhel M, McCormick M, Saha S, McKenna S, Shelley M, Hargadon B, et al. Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration 2012;83:36-44. https://doi.org/10.1159/000330667
  25. Ghebre MA, Bafadhel M, Desai D, Cohen SE, Newbold P, Rapley L, et al. Biological clustering supports both "Dutch" and "British" hypotheses of asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2015;135:63-72. https://doi.org/10.1016/j.jaci.2014.06.035
  26. Bardin PG, Price D, Chanez P, Humbert M, Bourdin A. Managing asthma in the era of biological therapies. Lancet Respir Med 2017;5:376-8. https://doi.org/10.1016/S2213-2600(17)30124-8
  27. Scanlon ST, McKenzie AN. Type 2 innate lymphoid cells: new players in asthma and allergy. Curr Opin Immunol 2012;24:707-12. https://doi.org/10.1016/j.coi.2012.08.009
  28. Sears MR. Safe use of long-acting ${\beta}$-agonists: what have we learnt? Expert Opin Drug Saf 2011;10:767-78. https://doi.org/10.1517/14740338.2011.579900
  29. Park HW, Yang MS, Park CS, Kim TB, Moon HB, Min KU, et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy 2009;64:778-83. https://doi.org/10.1111/j.1398-9995.2008.01876.x
  30. Thomas M, Halpin DM, Miravitlles M. When is dual bronchodilation indicated in COPD? Int J Chron Obstruct Pulmon Dis 2017;12:2291-305. https://doi.org/10.2147/COPD.S138554
  31. Cho YS. Effective strategies for managing asthma exacerbations for precision medicine. Allergy Asthma Immunol Res 2017;9:463-5. https://doi.org/10.4168/aair.2017.9.6.463
  32. Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 2016;47:410-9. https://doi.org/10.1183/13993003.01359-2015